GSK's FIRST trial achieves progression-free survival milestone in advanced ovarian cancer
Portfolio Pulse from
GSK's phase III FIRST-ENGOT-OV44 trial has successfully met its primary endpoint, demonstrating that the addition of Jemperli to chemotherapy and Zejula maintenance significantly improves progression-free survival in advanced ovarian cancer.
December 20, 2024 | 9:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's phase III trial for advanced ovarian cancer treatment has met its primary endpoint, showing significant improvement in progression-free survival with Jemperli and Zejula.
The successful trial results are likely to boost investor confidence in GSK's oncology portfolio, potentially leading to a positive impact on the stock price. The achievement of the primary endpoint in a phase III trial is a significant milestone, indicating potential for future revenue growth from these treatments.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100